Attached files
| file | filename |
|---|---|
| 8-K - PACIFICHEALTH LABORATORIES INC | v238922_8k.htm |
Exhibit 99.1
For Immediate Release:
|
Contact:
|
Stephen Kuchen, CFO
732-739-2900, x603
skuchen@pacifichealthlabs.com
|
PACIFICHEALTH LABORATORIES ANNOUNCES 3RD QUARTER RESULTS;
REMAINS PROFITABLE YEAR TO DATE
MATAWAN, NJ, November 2, 2011 – PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading sports nutrition company, today reported its financial results for the quarter and nine months ended September 30, 2011.
Third Quarter & Nine Months 2011 vs. 2010 Financial Results
Revenues were $1,971,624 for the third quarter and $5,948,461 for the nine months ended September 30, 2011 compared to $1,999,489 and $6,204,060, respectively, for the same periods in 2010. Net loss for the third quarter was ($116,675), or ($0.01) per share, and net income was $2,324, or $0.00 per diluted share, for the nine months ended September 30, 2011 compared to net losses of ($87,371), or ($0.01) per share, and ($219,876), or ($0.01) per share, for the same periods in 2010. Sales and marketing expenses increased $90,397 to $414,453 in the third quarter and increased $75,093 to $983,496 for the nine months ended September 30, 2011 compared to the same periods in 2010 primarily as a result of increased advertising expenses. General and administrative expenses decreased $108,069, or 17%, to $529,585 in the third quarter and decreased $568,188, or 26%, to $1,578,059 for the nine months ended September 30, of 2011 compared to the same periods in 2010 primarily as a result of a reduction in personnel and personnel related expenses.
At September 30, 2011, the Company had cash, cash equivalents, and other short-term investments of $1,114,840 compared to $284,165 at December 31, 2010, which increased primarily due to two private placements completed in 2011.
Fred Duffner, President and CEO of PacificHealth Laboratories, said, “We continued to make progress. Although total endurance sales for the three month period were flat year over year, we had strong growth in a number of our key channels: ecommerce sales were up 75%, sports specialty was up 32%, outdoor retailers were up 50% and international increased 26%. This growth was somewhat offset by the fact that our major retailers continue to reduce inventory in their supply chain. Additionally, the current period reflects a loss in revenues of approximately $36,000 from FORZE™ that we no longer market.”
Mr. Duffner added, “I am pleased to see continued momentum and sales from our newest products, 2ND SURGE® and ACCEL RECOVER™. 2ND SURGE and ACCEL RECOVER are now found in the top 1,000 GNC stores, and 2ND SURGE is also now carried by Vitamin
- more -
Shoppe. Consumer response, particularly to 2ND SURGE, has been gratifying. One of our goals was to increase our presence on Facebook. We have over 3,600 fans on our Facebook page and that is up 400% since June. Another noteworthy success was the re-launch of ENDUROX® EXCEL® Workout Supplement. At one time ENDUROX EXCEL was one of our largest and most profitable products. This year we reestablished distribution with our major retailers and we are seeing a significant increase in sales year over year.”
Mr Duffner concluded, “This continues to be a challenging environment. Cost of raw materials, particularly protein, is growing by double digits. However, in 2011 we made the necessary changes to position ourselves for growth. Our advertising and marketing campaigns have reestablished our brands with the endurance athlete. We introduced two new products and restarted our research program. We are far better positioned to grow our ecommerce business. We are not yet where we want to be, but we are clearly moving toward that goal.”
About PacificHealth Laboratories. Inc.
PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI’s principal areas of focus include sports performance and weight loss. To learn more, visit www.pacifichealthlabs.com.
Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects," "plans," "will,, "estimates," "forecasts," "projects," or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
- more -
SELECTED FINANCIAL DATA:
|
PACIFICHEALTH LABORATORIES, INC.
|
|
STATEMENTS OF OPERATIONS
|
|
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2011 AND 2010
|
|
(UNAUDITED)
|
|
Three Months
|
Nine Months
|
|||||||||||||||
|
Ended September 30,
|
Ended September 30,
|
|||||||||||||||
|
2011
|
2010
|
2011
|
2010
|
|||||||||||||
|
Revenues:
|
||||||||||||||||
|
Net product sales
|
$ | 1,971,624 | $ | 1,999,489 | $ | 5,948,461 | $ | 6,204,060 | ||||||||
|
Cost of goods sold
|
1,120,865 | 1,123,711 | 3,332,367 | 3,369,381 | ||||||||||||
|
Gross profit
|
850,759 | 875,778 | 2,616,094 | 2,834,679 | ||||||||||||
|
|
||||||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Sales and marketing
|
414,453 | 324,056 | 983,496 | 908,403 | ||||||||||||
|
General and administrative (Includes related party consulting
|
||||||||||||||||
|
of $48,000, $22,000, $139,000 and $22,000, respectively)
|
529,585 | 637,654 | 1,578,059 | 2,146,247 | ||||||||||||
|
Research and development
|
16,141 | - | 40,936 | - | ||||||||||||
|
|
960,179 | 961,710 | 2,602,491 | 3,054,650 | ||||||||||||
|
(Loss) income before other (expense) income and
|
||||||||||||||||
|
provision for income taxes
|
(109,420 | ) | (85,932 | ) | 13,603 | (219,971 | ) | |||||||||
|
Other (expense) income:
|
||||||||||||||||
|
Other income
|
- | - | 2,100 | 4,000 | ||||||||||||
|
Interest income
|
112 | 286 | 391 | 791 | ||||||||||||
|
Interest expense
|
(7,367 | ) | (1,725 | ) | (13,770 | ) | (4,696 | ) | ||||||||
| (7,255 | ) | (1,439 | ) | (11,279 | ) | 95 | ||||||||||
|
(Loss) income before provision for income taxes
|
(116,675 | ) | (87,371 | ) | 2,324 | (219,876 | ) | |||||||||
|
Provision for income taxes
|
- | - | - | - | ||||||||||||
|
Net (loss) income
|
$ | (116,675 | ) | $ | (87,371 | ) | $ | 2,324 | $ | (219,876 | ) | |||||
|
Basic (loss) income per share
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | 0.00 | $ | (0.01 | ) | |||||
|
|
||||||||||||||||
|
Diluted (loss) income per share
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | 0.00 | $ | (0.01 | ) | |||||
|
Weighted average common shares - basic
|
20,865,257 | 16,366,561 | 19,100,056 | 16,032,559 | ||||||||||||
|
Weighted average common shares - diluted
|
20,865,257 | 16,366,561 | 19,330,073 | 16,032,559 | ||||||||||||
- more -
|
PACIFICHEALTH LABORATORIES, INC.
|
|
BALANCE SHEETS
|
|
(UNAUDITED)
|
|
ASSETS
|
||||||||
|
September 30,
|
December 31,
|
|||||||
|
2011
|
2010
|
|||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 1,039,840 | $ | 134,165 | ||||
|
Other short-term investments
|
75,000 | 150,000 | ||||||
|
Accounts receivable, net
|
728,414 | 416,722 | ||||||
|
Inventories, net
|
711,596 | 596,317 | ||||||
|
Prepaid expenses
|
124,726 | 64,780 | ||||||
|
Total current assets
|
2,679,576 | 1,361,984 | ||||||
|
Property and equipment, net
|
26,939 | 52,531 | ||||||
|
Deposits
|
10,895 | 10,895 | ||||||
|
Total assets
|
$ | 2,717,410 | $ | 1,425,410 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Line of credit
|
$ | 37,500 | $ | 75,000 | ||||
|
Notes payable
|
39,354 | 20,670 | ||||||
|
Accounts payable and accrued expenses (Includes related
|
||||||||
|
party of $48,000 and $11,000, respectively)
|
872,507 | 713,184 | ||||||
|
Deferred revenue
|
65,801 | 60,836 | ||||||
|
Total current liabilities
|
1,015,162 | 869,690 | ||||||
|
Stockholders' equity:
|
||||||||
|
Common stock, $.0025 par value; authorized
|
||||||||
|
50,000,000 shares; issued and outstanding:
|
||||||||
|
20,865,257 and 16,485,257 shares, respectively
|
52,163 | 41,213 | ||||||
|
Additional paid-in capital
|
21,296,223 | 20,162,969 | ||||||
|
Accumulated deficit
|
(19,646,138 | ) | (19,648,462 | ) | ||||
| 1,702,248 | 555,720 | |||||||
|
Total liabilities and stockholders' equity
|
$ | 2,717,410 | $ | 1,425,410 | ||||
# # #